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ScienceDirectMitochondria are essential organelles that provide cellular
energy and buffer cytoplasmic calcium. At the same time they
produce damaging reactive oxygen species and sequester
pro-apoptotic factors. Hence, eukaryotes have evolved
exquisite homeostatic processes that maintain mitochondrial
integrity, or ultimately remove damaged organelles. This
subject has garnered intense interest recently following the
discovery that two Parkinson’s disease genes, PINK1 and
parkin, regulate mitochondrial degradation (mitophagy). The
molecular details of PINK1/Parkin-induced mitophagy are
emerging but much of our insight derives from work using
cultured cells and potent mitochondrial toxins, raising
questions about the physiological significance of these
findings. Here we review the evidence supporting PINK1/Parkin
mitophagy in vivo and its causative role in neurodegeneration,
and outline outstanding questions for future investigations.
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The PINK1–Parkin pathway
Mitochondria are a nexus of life and death of eukaryotic
cells, performing a number of critical functions, including
generating cellular energy, buffering cytosolic calcium flux,
promoting lipid metabolism, and sequestering the cell
death machinery. It has long been thought that malfunction
of the mechanisms that regulate mitochondrial quality
control (mitoQC) are a major driving force of normal ageing
[1]. Moreover, failure of mitoQC mechanisms, leading towww.sciencedirect.com elevated oxidative stress, is strongly linked to age-related
conditions such as neurodegeneration [2,3].
Most of the cellular chemical energy, in the form of
adenosine triphosphate (ATP), is produced in the mito-
chondrial matrix via the process of oxidative phosphory-
lation (OXPHOS). This process relies on electron flow via
the electron transport chain components in the inner
mitochondrial membrane, culminating in the reduction
of oxygen in the matrix and the generation of a membrane
potential across the inner membrane (DCm). However, a
deleterious side-product of this process is the generation
of highly reactive free radicals, termed reactive oxygen
species (ROS), that have the potential to damage macro-
molecules including proteins, lipids and nucleic acids. To
combat this, there are multiple intervention points to
protect the overall integrity of the mitochondrial network.
First, mitochondria contain an abundance of anti-oxidants
such as superoxide dismutase and glutathione to prevent
ROS-induced damage. Second, there are a broad collec-
tion of cellular factors that repair or replace damaged
mitochondrial components, including mitochondrial pro-
teases, mitochondrial chaperones, DNA repair enzymes
and the ubiquitin–proteasome system. Finally, when
mitochondrial damage becomes too extensive the
entire mitochondrion can be selectively degraded in
the lysosome through a process referred to as mitophagy.
Mitophagy was little studied before 2008, when seminal
work in the laboratory of Richard Youle showed that two
proteins linked to Parkinson’s disease (PD), Parkin, a
cytosolic ubiquitin ligase, and PINK, a mitochondrially
targeted kinase, play key roles in this process. The
current prevailing model posits that under basal condi-
tions, ‘healthy’ mitochondria, that is those with a high
DCm, import and degrade PINK1 [4,5]. This process
serves to constitutively repress a key degradation signal.
Upon mitochondrial damage, typically modelled by the
dissipation of DCm with uncoupling agents or mitochon-
drial poisons, PINK1 import is blocked and instead
accumulates on the outer mitochondrial membrane
(OMM). PINK1 then phosphorylates ubiquitin (likely
residual ubiquitin-modified OMM proteins) at Ser65
[6,7,8]. This stimulates the recruitment of cytosolic
Parkin to the mitochondrial surface [9] via the direct
binding of Parkin to phospho-ubiquitin chains. Parkin
is then also phosphorylated by PINK1 at an equivalent
Ser65 residue within its N-terminal ubiquitin-like
domain [10]. Both events stimulate the ubiquitin-ligase
activity of Parkin allowing it to ubiquitinate a host ofCurrent Opinion in Genetics & Development 2017, 44:47–53
48 Molecular and genetic bases of diseaseOMM targets [11,12]. The additional supply of local
ubiquitin provides further substrate for PINK1, promot-
ing additional Parkin recruitment in a feed-forward mech-
anism [12]. The high density of ubiquitinated OMM
proteins leads ultimately to the recruitment of ubiquitin
adaptor proteins, which in turn promote engulfment of
the depolarized mitochondria by autophagosomes
[13,14].
The mechanism by which PINK1 and Parkin promote
mitophagy, as described above, is attractive for several
reasons; first, this model offers an explanation for the
longstanding evidence that mitochondrial defects are
central to the pathogenicity of PD, including the obser-
vations that mitochondrial toxins cause PD in humans
and animal models, that PD patients have systemic
mitochondrial complex I deficits, and that DA neurons
in elderly individuals accumulate high levels of mtDNA
mutations relative to other neuronal subtypes [15–19].
Second, these findings would explain the protective
effects of PINK1 and Parkin overexpression from expo-
sure to mitochondrial toxins [20–22]. Third, the unique
physiological characteristics of substantia nigra neurons
place an extreme demand on mitochondrial function to
meet their high energy demand and calcium buffering
requirements, which may explain the selective vulner-
ability of these neurons to loss of mitoQC processes
[23].
While there is now wide acceptance for the role of PINK1
and Parkin in mitophagy, and the mechanisms by which
these factors act in this process, it is also important to
recognize the limitations of the work that support this
model. In particular, much of the work that supports our
current understanding of PINK1 and Parkin derives from
the use of high concentrations of protonophores such as
CCCP/FCCP to dissipate the mitochondrial membrane
potential. Of note, these uncoupling agents have the
potential to depolarise other cellular compartments such
as the lysosome, and are frequently used at concentra-
tions an order of magnitude greater than that needed to
depolarise mitochondria. Such concerns were substanti-
ated with evidence that this effect may in fact be caused
by the non-specific acidification of the cytosol [24],
underscoring the need for more precise targeting of
mitochondria to study the cell biology. Another concern
with much of the work that supports our understanding
of the role of PINK1 and Parkin in mitophagy is that it
derives from the use of cultured cells that overexpress
these factors. While it is conceivable that these extreme
measures simply amplify or accelerate normal physio-
logical processes that would be otherwise difficult to
detect, these approaches also make it unclear how such
findings translate to physiological conditions. In the
remainder of this article, we briefly summarize some
of the findings that challenge the roles of PINK1 and
Parkin in mitophagy, and the evidence supporting theirCurrent Opinion in Genetics & Development 2017, 44:47–53 role in this process using more physiologically relevant
model systems.
PINK1/Parkin function in neurons
One of the early challenges to the model that PINK1 and
Parkin promote mitophagy is that much of the initial data
in support of this model derived from cancerous cell lines.
Cancer cells typically rely on glycolysis for energy pro-
duction (the Warburg effect) and could potentially toler-
ate substantial loss of mitochondria, whereas neurons rely
heavily on OXPHOS for energy production. Indeed, cells
forced to rely on OXPHOS greatly inhibits PINK1/Parkin
mitophagy upon loss of DCm [25]. Furthermore, early
studies investigating PINK1/Parkin mitophagy in pri-
mary neurons failed to detect Parkin translocation and/
or mitochondrial degradation upon mitochondrial depo-
larization, and mutations in parkin did not influence the
pathogenicity of mitochondrial disruption in mice, which
further cast doubt on the physiological relevance of
mechanistic models derived from studies using cell lines
[26,27]. However, subsequent studies of primary neurons
have reported Parkin translocation to depolarized mito-
chondria, although this process appeared to be restricted
to somatodendritic regions and displayed delayed kinet-
ics relative to non-neuronal cells [28]. Another study of
hippocampal neurons reported rapid that Parkin and
autophagosome recruitment could occurr in distal axons
[29]. Notably, in contrast to using pharmacological
agents, Ashrafi et al. induced mitochondrial damage via
the mtKillerRed-generated ROS. Importantly, this
approach offers an alternative to chemical toxification
which is more amenable to in vivo studies. It will be
interesting to learn whether analysing PINK1/Parkin
mitophagy using this approach in animals will recapitu-
late aspects of the current model. In summary, current
evidence from cultured neurons does provide support for
PINK1/Parkin mitophagy, nevertheless the still rely on
Parkin overexpression.
Triggers for PINK1/Parkin function
To address concerns with off-target effects of the depo-
larizing agents used in early studies of PINK1 and Parkin,
more recent studies have used mitochondria-specific poi-
sons such as oligomycin and antimycin A [12,30], and
have observed comparable effects to CCCP/FCCP
uncoupling. A study using live imaging of cultured cells
potentially offers additional support for the role of PINK1
and Parkin in the degradation of depolarized mitochon-
dria by showing that mitochondrial fission products with
decreased membrane potential have a higher probability
of undergoing autophagy [31]. However, whether this
mitophagy is mediated by PINK1 and Parkin has not
been definitively established. Moreover, the mitochon-
dria targeted for degradation in this live cell imaging
study display only a relatively small decrease in mem-
brane potential, far below that seen in experiments
involving cells treated with depolarizing agents, furtherwww.sciencedirect.com
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mitophagy. Finally, Ca2+-pacemaking has been shown to
trigger more substantial mitochondrial depolarization
[32], yet there is no evidence that this mitochondrial
depolarization triggers PINK1–Parkin mediated mito-
phagy. Finally, recent work has shown that unfolded
matrix proteins trigger PINK1–Parkin-mediated mito-
phagy without triggering mitochondrial depolarization
[33,34]. Together, these studies pose serious challenges
to the model that mitochondrial depolarization is the true
physiological stimulus for PINK1–Parkin mediated
mitophagy.
PINK1/Parkin in animal models: of mice and
flies
PINK1 and Parkin have also been extensively studied
using in vivo model systems. In particular, pioneering
studies in the fruit fly Drosophila were the first to demon-
strate a role for Parkin in mitochondrial maintenance [35],
and to link PINK1 and Parkin in a common biological
pathway [36,37]. PINK1/parkin deficiency in Drosophila
triggers the accumulation of enlarged, damaged mito-
chondria in sperm, flight muscle and dopaminergic neu-
rons, suggesting that this pathway influences mitochon-
drial integrity in energetically demanding tissues [35–37].
To directly test the hypothesis that PINK1 and Parkin
promote mitophagy in vivo under physiological condi-
tions, Vincow et al. used an innovative proteomic
approach employing quantitative mass spectrometry to
monitor mitochondrial protein turnover in Drosophila
heads [38], which has provided some compelling evi-
dence. Working on the premise that under physiologically
constant conditions mitochondrial components would be
degraded and replaced at a constant rate to maintain
steady-state levels, the accumulation of heavy isotope-
labelled mitochondrial proteins was monitored in Pink1
and parkin mutants compared to wild-type flies. These
experiments revealed that the half-life of many mitochon-
drial proteins was significantly increased in parkin
mutants in a pattern that closely resembled that of
autophagy-defective Atg7 mutants, thus supporting a role
for Parkin in mitophagy.
While studies in Drosophila offer potential support for a
role of PINK1 and Parkin in mitophagy, they also leave
several questions unanswered, and raise new questions.
In particular, flight muscle disruption is apparent in young
Pink1 and parkin mutants, preceding any influence of age-
related mitochondrial damage, thus raising the possibility
that the role of PINK1 and Parkin in flight muscle may
not involve mitophagy. Similarly, mitochondrial defects
in the germline of Pink1 and parkin mutants also occur
during the development of these tissues and seem more
likely to result from altered mitochondrial fission/fusion,
rather than a defect in mitophagy [39,40], again chal-
lenging the concept that these defects involve mito-
phagy. Moreover, it is also hard to reconcile the geneticwww.sciencedirect.com rescue of Pink1 mutants by parkin overexpression [36,37]
with the apparent absolute requirement for PINK1 to
promote mitophagy in cultured vertebrate cells [30].
Additionally, although parkin mutants showed a dra-
matic reduction in mitochondrial protein turnover, the
influence of Pink1 on mitochondrial turnover was
restricted primarily to membrane-spanning respiratory
chain components. parkin mutants also had a dispropor-
tionately large effect on membrane-spanning respiratory
chain components, suggesting a novel mitochondrial
protein-selective feature of PINK1 and Parkin on mito-
chondrial protein degradation.
PINK1 and Parkin have also been studied extensively in
mice. Perhaps the most obvious disconnect is the appar-
ent lack of gross physiological, neurological or behavioral
phenotypes in PINK1/parkin knockout mice, which is not
easy to reconcile with the notion that PINK1/Parkin
mitophagy is an important cell survival mechanism. How-
ever, two recent studies have reported that post-natal
conditional parkin knockout does result in loss of nigral
dopaminergic neurons [41,42], suggesting a compensatory
mechanism occurs during development in germline
knockouts. Although the nature of this compensatory
mechanism is currently unclear, Parkin-independent
mechanisms of mitophagy have been described and it
is possible that the induction of one or more of these
mechanisms may compensate for loss of parkin [43–45].
Nevertheless, this finding clearly indicates a discordance
between mouse and man since PINK1 or parkin loss
almost invariably leads to a profound neurodegeneration
in humans that can be evident as early as 3 years of age.
Although overt dopaminergic neuron degeneration is not
observed upon germline knockout of mouse homologs of
PINK1, parkin and other genes associated with recessive
forms of PD, a recent study of a mouse strain that
expresses a proof-reading defective version of the
mtDNA polymerase (POLG), known as the ‘mutator’
mouse [46,47], provides evidence that PINK1 and Parkin
play a role in mitochondrial quality control in this organ-
ism. Although mutator mice and parkin mutants display
no loss of dopaminergic neurons, mice that are homozy-
gous for the parkin knockout in the mutator background
revealed a significant degeneration of dopaminergic neu-
rons and motor deficits [48]. Moreover, the sensitivity to
this double hit showed a relative selectivity for nigral
dopaminergic neurons, a cardinal feature of PD. Surpris-
ingly however, there was no increase in the mtDNA
mutation frequency in the double mutants, suggesting
that the influence of parkin deletion in the mutator
background was not a consequence of a defect in the
selective elimination of mutation bearing mitochondria.
While the influence of Parkin on the mutator mouse
phenotype requires further examination, these findings
are at least consistent with a biological role of Parkin in
mitochondrial quality control.Current Opinion in Genetics & Development 2017, 44:47–53
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What is the physiological trigger?
Although there has been incredible progress in our under-
standing of the biological roles of PINK1 and Parkin and
mitophagy over the past 8 years following the seminal
work linking these factors to mitophagy, many important
questions remain about this pathway. For example, it
remains unclear whether mitochondrial depolarization is
the true physiological trigger of PINK1–Parkin pathway
induction. The recent finding that unfolded mitochon-
drial matrix proteins trigger pathway induction indepen-
dent of a reduction in membrane potential raises the
possibility that unfolded proteins are the true physiologi-
cal trigger of pathway induction [33,34]. However, it is far
from clear how unfolded matrix proteins may trigger
mitophagy. Moreover, substantial recent work indicates
that unfolded mitochondrial matrix proteins can trigger a
general cellular response to alleviate this stress [49], so the
finding that the PINK1–Parkin pathway also responds to
unfolded protein stress raises the question of how these
two pathways are coordinated to influence the decision of
whether to repair, or degrade the mitochondria that
harbour unfolded proteins.
What is the precise mechanism of PINK1/Parkin
mitoQC?
Another important unanswered question involves the
precise role of PINK1 and Parkin in mitochondrial quality
control. As mentioned above, parkin mutations influence
the phenotype of mutator mice, but this influence appears
to be independent of a role of Parkin in degrading
mutation-bearing mitochondria. Moreover, proteomic
studies in flies raise the possibility of a mitochondrial-
protein selective feature of PINK1 and Parkin. One
attractive model that offers a potential explanation for
these findings derives from recent work documenting the
existence of a piecemeal process of mitochondria quality
control—the formation of cargo-selective mitochondria
derived vesicles (MDVs) [50]. The function of MDVs
appear diverse but evidence strongly implicates a role in
the selective transport of oxidized mitochondrial compo-
nents for degradation in lysosomes [51–53]. Importantly,
PINK1 and Parkin have been linked to the formation and
trafficking of MDVs [54,55], as well as a third PD factor,
Vps35 [55,56]. Although MDVs have not been analysed
directly in vivo, and may prove extremely challenging,
this model would explain the selective degradation of
respiratory proteins in Drosophila parkin and Pink1
mutants. Moreover, such a vesicular pathway would also
potentially explain the finding that removal of parkin
influences the phenotypes of mutator mice without
affecting the frequency of mtDNA mutations. Given that
the mitochondrial genome encodes membrane spanning
components of the respiratory chain, the presence of
Parkin may mitigate the effects of mtDNA mutations
by selectively promoting the degradation of theCurrent Opinion in Genetics & Development 2017, 44:47–53 mutationally altered products of these mutations through
this vesicular pathway. Additional evidence in support of
this pathway is provided by the finding that genetic
studies in Drosophila revealed a striking interaction
between vps35 and parkin [57], providing strong support
for a common pathway. Important future challenges
involve the validation of this vesicular pathway in an
in vivo context, and the elucidation of the regulatory
mechanisms that influence the decision to activate whole-
sale mitochondrial degradation, or piecemeal degradation
through this vesicular pathway.
What are the mechanisms of mitochondrial component
turnover?
Lastly, while the proteomic assay of mitochondria protein
turnover is useful for monitoring mitochondrial protein
degradation, this approach is agnostic as to the precise
mechanism of mitochondrial protein degradation. For
many, seeing is believing, and proteomic and other bio-
chemical methods do not allow fine spatial and temporal
resolution to address where and when this turnover is
occurring. Hence, the recent reports of two transgenic
mouse models to monitor mitophagy in vivo are timely
[58,59]. One uses a matrix-targeted pH-sensitive variant
of GFP (mtKeima) while the other uses a tandem GFP-
RFP fusion targeted to the OMM (called ‘mito-QC’).
Both methods exploit the pH difference between rela-
tively neutral matrix or cytosol and the acidic lysosomal
lumen to induce a change in fluorescence. While these
valuable tools have not yet been used in the context of
PINK1/Parkin mitophagy, they have revealed that basal
mitophagy is surprisingly abundant but varies widely
between and even within a tissue or organ. Notably,
the mtKeima reporter showed elevated mitophagy by
hypoxia, mtDNA mutations and cancerous cells, but
was reduced with age, a high-fat diet and expression of
Huntingtin. While, there are still questions to address
concerning how well these reporters mirror mitochondrial
components, for example whether the reporter have a
similar half-life in lysosomes compared to mitochondrial
proteins and whether a proportion may be mis-localized
and reporting autophagy of other compartments, the stage
is set to now use these reporters to explore the in vivo
nature of PINK1/Parkin mitophagy. It will be particularly
interesting to investigate whether certain brain regions, in
particular the basal ganglia, have high levels of to mito-
phagy which require PINK1/Parkin.
Concluding remarks
In conclusion, the use of cell culture models and chemical
toxification of mitochondria has allowed the elucidation
of the molecular mechanism by which PINK1 and Parkin
signal the degradation of mitochondrial components,
although initial attempts to translate these findings
to neurons and animal models was controversial.
However, there is now mounting evidence in vivo and
importantly under physiological conditions supporting awww.sciencedirect.com
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over of mitochondria components. Nevertheless, it is still
unclear exactly what are the physiological stimuli that
signal the distinction between destruction and repair
processes. Ultimately, it also remains to be determined
whether stimulating this PINK1/Parkin mitoQC repre-
sents a viable therapeutic target. These outstanding
points seed the field for vigorous and insightful research
to come.
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